Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 12, 2010, Pages 2504-2509

  Shu, Xiao ^a,b   Nelbach, Lisa ^a   Weinstein, Michael M ^c,d   Burgess, Braydon L ^a   Beckstead, Jennifer A ^a   Young, Stephen G ^c,d   Ryan, Robert O ^a   Forte, Trudy M ^a,b  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

apolipoproteins; hyperlipoproteinemia; lipids; lipoproteins

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN A5 RECONSTITUTED HIGH DENSITY LIPOPROTEIN; CHOLESTEROL; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEINS; APOLIPOPROTEINS A; BINDING SITES; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HEPARIN; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; INJECTIONS, INTRAVENOUS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; MICE; MICE, KNOCKOUT; MUTAGENESIS, SITE-DIRECTED; MUTATION; RECEPTORS, LIPOPROTEIN; RECOMBINANT PROTEINS; TIME FACTORS; TRIGLYCERIDES;

EID: 78650419569     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.210815     Document Type: Article

References (31)

1. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86:943-949.
2. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176:1113-1120.
3. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75:473-486.
4. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts. Circulation. 2003;108:1546-1551.
5. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001; 294:169-173.
6. Van Der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, Chamuleau RA. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem. 2001; 276:44512-44520.
7. Forte TM, Shu X, Ryan RO. The ins (cell) and outs (plasma) of apoli-poprotein A-V. J. Lipid Res. 2009;50:S150-S155.
8. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apoli-poproteins. Clin Chem. 2005;51:351-359.
9. Nelbach L, Shu X, Konrad RJ, Ryan RO, Forte TM. Effect of apoli-poprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice. J Lipid Res. 2008;49:572-580.
10. Vaessen SFC, Dallinga-Thie GM, Ross CJD, Splint LJ, Castellani LW, Rensen PCN, Hayden MR, Schaap FG, Kuivenhoven JA. Plasma apoli-poprotein AV levels in mice are positively associated with plasma tri-glyceride levels. J Lipid Res. 2009;50:880-884.
11. Marcais C, Verges B, Charriere S, Pruneta V, Merlin M, Billon S, Perrot L, Drai J, Sassolas A, Pennacchio LA, Fruchart-Najib J, Fruchart JC, Durlach V, Moulin P. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest. 2005;115:2862-2869.
12. Oliva CP, Pisciotta L, Guardamagna O, Bellocchio A, Tarugi P, Schaap FG, Bertolini S, Calandra S. A novel sequence variant in apoA5 gene found in patients with severe hypertriglyceridemia. Atherosclerosis. 2006;188:215-217.
13. Oliva CP, Pisciotta L, Volti GL, Sambataro MP, Cantafora A, Bellocchio A, Catapano A, Tarugi P, Bertolini S, Calandra S. Inherited apoli-poprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2005;25:411-417.
14. Grosskopf I, Baroukh N, Lee SJ, Kamari Y, Harats D, Rubin EM, Pennacchio LA, Cooper AD. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyc-eriderich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol. 2005;25:2573-2579.
15. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J. Apolipoprotein AV accelerates plasma hydrolysis of triglyceriderich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem. 2005;280:21553-21560.
16. van der Vliet HN, Schaap FG, Levels JH, Ottenhoff R, Looije N, Wes-seling JG, Groen AK, Chamuleau RA. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun. 2002;295:1156-1159.
17. Schaap FG, Rensen PC, Voshol PJ, Vrins C, Van der Vliet HN, Chamuleau RA, Havekes LM, Groen AK, Van Dijk KW. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglycer-ide (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem. 2004;279:27941-27947.
18. Qu S, Perdomo G, Su D, D'Souza FM, Shachter NS, Dong HH. Effects of apoA-V on HDL and VLDL metabolism in apoC3 transgenic mice. J Lipid Res. 2007;48:1476-1487.
19. Lookene A, Beckstead JA, Nilsson S, Olivecrona G, Ryan RO. Apoli-poprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem. 2005;280:25383-25387.
20. Nilsson SK, Lookene A, Beckstead JA, Gliemann J, Ryan RO, Olivecrona G. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry. 2007;46: 3896-3904.
21. Dichlberger A, Cogburn LA, Nimpf J, Schneider WJ. Avian apoli-poprotein A-V binds to LDL receptor gene family members. J Lipid Res. 2007;48:1451-1456.
22. Beigneux AP, Davies BS, Gin P, Weinstein MM, Farber E, Qiao X, Peale F, Bunting S, Walzem RL, Wong JS, Blaner WS, Ding ZM, Melford K, Wongsiriroj N, Shu X, de Sauvage F, Ryan RO, Fong LG, Bensadoun A, Young SG. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 2007;5:279-291.
23. Gin P, Yin L, Davies BSJ, Weinstein MM, Ryan RO, Bensadoun A, Fong LG, Young SG, Beigneux AP. The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons. J Biol Chem. 2008;283:29554-29562.
24. Beckstead JA, Oda MN, Martin DD, Forte TM, Bielicki JK, Berger T, Luty R, Kay CM, Ryan RO. Structure-function studies of human apoli-poprotein A-V: a regulator of plasma lipid homeostasis. Biochemistry. 2003;42:9416-9423.
25. Lee EC, Desai U, Gololobov G, Hong S, Feng X, Yu X-C, Gay J, Wilganowski N, Gao C, Du L-L, Chen J, Hu Y, Zhao S, Kirkpatrick L, Schneider M, Zambrowicz BP, Landes G, Powell DR, Sonnenburg WK. Identification of a new functional domain in angiopoietin-like 3 (angptl3) and angiopoietin-like 4 (angptl4) involved in binding and inhibition of lipoprotein lipase (lpl). J Biol Chem. 2009;284:13735-13745.
26. Dallinga-Thie GM, Zonneveld-de Boer AJ, Van Vark-van der Zee LC, Van Haperen R, Van Gent T, Jansen H, De Crom R, Van Tol A. Appraisal of hepatic lipase and lipoprotein lipase activities in mice. J Lipid Res. 2007;48:2788-2791.
27. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc. 2003;290:2292-2300.
28. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet. 2002;11:3031-3038.
29. Talmud PJ, Cooper JA, Hattori H, Miller IP, Miller GJ, Humphries SE. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes: results from the Northwick Park Heart Study II. Diabetologia. 2006;49:2337-2340.
30. Pullinger CR, Aouizerat BE, Movsesyan I, Durlach V, Sijbrands EJ, Nakajima K, Poon A, Dallinga-Thie GM, Hattori H, Green LL, Kwok P-Y, Havel RJ, Frost PH, Malloy MJ, Kane JP. An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients. J Lipid Res. 2008;49:1846-1854.
31. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglycer-ide-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1584-1586.